Bernstein analyst William Pickering raised the firm’s price target on Vertex Pharmaceuticals to $390 from $380 and keeps an Outperform rating on the shares. The firm notes Vertex reported solid Q2 results, beating consensus by 3% on revenue and in line on adjusted EPS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $399 from $384 at Barclays
- Vertex Pharmaceuticals raises FY23 CF product revenue to $9.7B-$9.8B
- Vertex Pharmaceuticals reports Q2 EPS $3.52, consensus $3.88
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex Pharmaceuticals price target raised to $400 from $350 at BofA